Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy - Trial NCT06389721
Access comprehensive clinical trial information for NCT06389721 through Pure Global AI's free database. This phase not specified trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
N/A
Oct 31, 2024
Jan 31, 2027
Primary Outcome
Safety and adverse events (AEs)
Summary
Cohort 1: To track the onset and progression of a condition called chemotherapy-induced
 peripheral neuropathy (CIPN).
 
 Cohort 2: To track the onset and progression of a condition called chemotherapy-induced
 peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation
 (stimulation of the brain) with a device called a closed-loop brain-computer interface
 (clBCI) to see if can help to prevent pain due to CIPN.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06389721
Non-Device Trial